Background-Patients with ischemic stroke or transient ischemic attack presumably related to patent foramen ovale (PFO) are at risk for recurrent cerebrovascular events. Differences in long-term clinical outcome were investigated among patients with percutaneous PFO closure and those who received medical treatment. Methods and Results-Between 1994 and 2000, 308 consecutive patients with cerebrovascular events presumably related to PFO underwent either percutaneous PFO closure (150 patients) or medical treatment (158 patients). Patients were followed up prospectively for up to 15 years. Seven patients were lost during follow-up. The primary outcome was a composite of stroke, transient ischemic attack, or peripheral embolism. We analyzed 103 propensity score-matched pairs of patients who underwent percutaneous PFO closure or medical treatment. At a median follow-up of 9 years, the primary composite outcome occurred in 11 patients slated to PFO closure (11%) and 22 patients slated to medical treatment (21%; hazard ratioϭ0.43; 95% confidence intervalϭ0.20 -0.94; Pϭ0.033). The treatment effect was driven by a decrease in the risk of transient ischemic attack of 5% versus 14%, respectively (hazard ratioϭ0.31; 95% confidence intervalϭ0.10 -0.94; Pϭ0.039). The risk of all-cause (6% in both groups) and cardiovascular (3% in both groups) mortality appeared to be identical. Conclusion-In this long-term observational, propensity score-matched study, percutaneous PFO closure was more effective than medical treatment for the secondary prevention of recurrent cerebrovascular events among patients with PFO-related transient ischemic attack or stroke. (Circulation. 2012;125:803-812.) contributed equally to this article. The online-only Data Supplement is available with this article at http://circ.ahajournals.org/lookup/suppl/
S troke remains the third leading cause of mortality and the most important cause of serious, long-term disability. 1 A classic cause is not found in up to 40% of ischemic strokes, which are referred to as cryptogenic. 2 The association of patent foramen ovale (PFO) with cryptogenic stroke 3, 4 suggests paradoxical embolism as the underlying pathophysiological mechanism. This concept was recently extended from young adults to older patients. 5 A meta-analysis of 23 case-control studies 6 suggested that the odds of PFO were 2.9 times higher in patients with cryptogenic stroke compared with controls (95% confidence interval [CI], 2.1-4.0). Patients with ischemic stroke or transient ischemic attack (TIA) presumably related to PFO are at risk for recurrent cerebrovascular events. Secondary prevention with antiplatelet agents or coumarin (used as placeholder for all vitamin K antagonists) is associated with an increased bleeding risk. Percutaneous PFO closure eliminates the potential pathway of paradoxical embolism. It may obviate the need for longterm medical therapy but is associated with a small periprocedural risk and the cost of the intervention. The annual risk of recurrent cerebrovascular events with antiplatelet agents or coumarin is estimated at 1% to 12%. [7] [8] [9] [10] [11] [12] [13] The risk of recurrence is higher among patients with PFO and an associated atrial septal aneurysm (ASA). 7, 10 Percutaneous PFO closure has been shown to be safe and feasible with a variety of devices. 14 -23 Observational data, including an early analysis of our stroke registry, 24 suggest a lower risk of recurrent cerebrovascular events than with medical treatment alone. 13, 24, 25 Several randomized trials are currently underway to compare the safety and efficacy of percutaneous PFO closure with medical treat-ment for the secondary prevention of cerebrovascular events. However, those trials suffer from slow patient recruitment because most high-risk patients are treated by percutaneous PFO closure outside of randomized trials.
Clinical Perspective on p 812
To investigate the therapeutic value of percutaneous PFO closure compared with medical treatment, we analyzed longterm outcomes, including a propensity score (PS)-matched comparison, in a prospective cohort study of consecutive patients with PFO and cryptogenic stroke or TIA who underwent PFO closure or medical treatment and were followed up for a median of 10 years.
Methods

Patients
All patients with ischemic stroke or TIA seen by our University Hospital Stroke Center between January 1994 and August 2000 were prospectively entered into the Bern Stroke Registry. 24 The diagnosis of TIA was based on the time until full resolution of symptoms. A transient episode of neurological dysfunction lasting Ͻ24 hours with or without evidence of brain damage on computed tomography or magnetic resonance was classified as a TIA. Ischemic stroke was defined as a sudden new focal neurological deficit lasting Ͼ24 hours with evidence of brain damage on computed tomography or magnetic resonance. All patients with cryptogenic stroke or TIA routinely underwent contrast transesophageal echocardiography (TEE). Minimal workup included brain imaging (computed tomography and/or magnetic resonance imaging); Doppler and color Duplex examination of the extracranial carotid, vertebral, and basal intracranial arteries; ECG and Holter ECG; contrast TEE; and blood testing. The cerebrovascular event was considered to be presumably related to PFO if the presence of a PFO with or without ASA (spontaneous or inducible interatrial right-to-left shunt during contrast TEE) was established and other cardiac, aortic, or cerebrovascular causes were excluded. Patients with stroke of known origin and patients without PFO were excluded. In particular, patients with permanent or paroxysmal atrial fibrillation or major aortic plaques were excluded. This left 308 consecutive patients with cerebrovascular embolism presumably related to PFO. Of those, 150 patients underwent percutaneous PFO closure, and 158 patients were treated medically. The individual treatment decision was based on a consensus between neurologist and patient. The study complied with the Declaration of Helsinki regarding investigations in humans and was approved by the Institutional Ethics Committee at Bern University Hospital, Bern, Switzerland. Patients gave written informed consent.
Data Collection
Patients were actively followed up for major adverse events through the use of questionnaires, personal interviews, or telephone contacts. Questions addressed survival, recurrent cerebrovascular or peripheral embolic events, and device-or medication-related problems. Vital status was ascertained from hospital records and municipal civil registries. For suspected events, relevant medical records and documentation of imaging procedures were collected from hospitals and private practitioners. Patients with suspected recurrent cerebrovascular events were re-examined by a neurologist, including an imaging study of the brain. All suspected events were adjudicated by an unblinded senior neurologist. Baseline clinical and procedural characteristics and all follow-up data were entered into a dedicated database. An academic clinical trials unit (CTU Bern, Bern University Hospital) was responsible for central data audits and maintenance of the database.
Procedures
The diagnosis of PFO and ASA was based on contrast TEE with aerated colloid solution injected into an antecubital vein at the end of a vigorous and sustained Valsalva maneuver. PFO was defined as a documented right-to-left shunt through a gap between the septum primum and secundum. ASA was diagnosed as abnormally redundant interatrial septum with an excursion of Ն10 mm into the right or left atrium and a diameter at the base of the aneurysm of at least 15 mm. 26 Spontaneous or provoked right-to-left shunt was semiquantitatively graded according to the amount of bubbles detected in the left atrium after crossing the interatrial septum on a still frame: grade 0ϭnone, grade 1ϭminimal (1-5 bubbles), grade 2ϭmoderate (6 -20 bubbles), and grade 3ϭsevere (Ͼ20 bubbles). 4 Patients undergoing medical treatment received coumarin or antiplatelet agents (acetylsalicylic acid or clopidogrel at the discretion of the neurologist). Coumarin was prescribed with a target international normalized ratio of 2.0 to 3.0, acetylsalicylic acid at a dose of 100 to 300 mg, and clopidogrel at a dose of 75 mg once daily. Patients undergoing percutaneous PFO closure underwent the procedure under local anesthesia and fluoroscopic guidance. [21] [22] [23] Six closure device types were used according to historic availability. They included 54 Amplatzer PFO, 42 PFO STAR, 27 Sideris Buttoned, 10 Angel Wing, 9 Amplatzer ASD, and 8 CardioSEAL occluders. A transthoracic contrast echocardiography was performed within 24 hours of percutaneous PFO closure to document correct and stable device position, and acetylsalicylic acid 100 mg once daily was prescribed for 6 months. A contrast TEE was repeated 6 months after percutaneous PFO closure to detect residual shunts and to exclude thrombus on the device. Medical treatment with antiplatelet agents was discontinued in 93 of 150 patients after 6 months, whereas 57 patients continued medical treatment with acetylsalicylic acid 100 mg once daily owing to a residual shunt (26 patients) or the presence of coronary artery disease as documented by incidental coronary angiography (31 patients). 27 
Definitions
The entry date into the study was defined as the date of the cerebrovascular index event (ischemic stroke or TIA) that resulted in the referral to our Stroke Center with consideration of PFO closure regardless of the final treatment decision. The prespecified primary end point was the composite of stroke, TIA, or peripheral embolism up to a maximum follow-up of 15 years. Secondary end points included stroke, TIA, peripheral embolism, overall death, cardiac death, vascular death, major bleeding, and the composites of stroke or death and of stroke, TIA, peripheral embolism, or death. Cardiac deaths included any deaths resulting from an immediate cardiac cause; procedure-related deaths, including those related to concomitant treatment; unwitnessed deaths; and deaths resulting from unknown causes. Vascular deaths included all deaths related to noncoronary vascular causes. All other deaths were classified as noncardiovascular. Bleeding events were classified as lifethreatening or disabling, major but not life-threatening, or minor.
Statistical Analysis
For this superiority analysis, the sample size was driven by the availability of patients. Successful PS matching in 75% of patients would yield 113 pairs, which would result in Ϸ80% power to detect a hazard ratio (HR) of 0.40 assuming that 2.5 patients per 100 patient-years experienced at least 1 event covered by the primary composite end point and a median follow-up of 10 years. Including all 158 and 150 patients in the analysis would result in 80% power to detect an HR of 0.48 under the same assumptions. The PSs for undergoing PFO closure were estimated with a probit model (see the Appendix in the online-only Data Supplement). We used Cox proportional hazards models to derive HRs comparing the 2 groups, crude and adjusted with the inverse probability of treatment (IPT) as weight in the analysis of all patients and accounting for the 1:1 matching in the analysis of PS-matched patients (see the Appendix in the online-only Data Supplement). The analysis of the primary composite end point was performed overall and stratified according to the presence or absence of ASA, age, sex, severity of right-to-left shunt, Ͼ1 cerebrovascular event at baseline, and type of index event. Primary comparisons were performed in analogy to the intention-totreat principle of randomized trials and based on the initial treatment decision on PFO closure or medical treatment alone. In addition, we performed an exploratory analysis of all outcomes, splitting the follow-up time into episodes with medical treatment and episodes after (crossover to) PFO closure and extending the model to account for multiple events occurring in the same patient. All P values and 95% CIs are 2 sided, without adjustment for multiple comparisons. Analyses were performed with Stata (release 11).
Results
Of the 150 patients with percutaneous PFO closure and 158 patients with medical treatment, 301 (98%) were available for follow-up to a maximum of 15 years. Two patients with percutaneous PFO closure and 5 patients with medical treatment were lost during follow-up. The median follow-up duration was 10 years (range, 8 -15 years) in patients undergoing percutaneous PFO closure and 11 years (8 -15 years) in patients undergoing medical treatment. The accumulated patient-years were 1582 and 1685, respectively, in the 2 groups. Table 1 presents a comparison of patients before PS matching. Patients undergoing percutaneous PFO closure were more likely to be hypercholesterolemic, to have a larger right-to-left shunt, and to have suffered Ͼ1 cerebrovascular event than patients undergoing medical treatment. PFO closure was successful in 148 patients (99%) and failed in 2. One of these patients underwent surgical PFO closure; the other patient was treated medically. During follow-up, 1 additional patient in the PFO closure group underwent surgical PFO closure after a recurrent TIA, and 4 patients underwent implantation of a second device owing to persistence of a residual shunt, in 1 case after a recurrent TIA ( Figure 1 ). Complete PFO closure as assessed by contrast TEE at 6 months was observed in 123 patients (82%), whereas a small, moderate, and large shunt persisted in 15 patients (10%), 5 patients (3%), and 7 patients (5%), respectively. An asymptomatic device thrombus was detected in 2 patients and resolved with oral anticoagulation. In the medical treatment group, 43 patients (27%) crossed over to subsequent percu- taneous (nϭ38) or surgical (nϭ5) PFO closure at a median of 3.9 years after the index event ( Figure 1 ). Closure was prompted by a recurrent thromboembolic event in 13 patients, by a major bleeding event in 2 patients, and at patient or physician discretion in the remainder. Table I in the onlineonly Data Supplement presents a comparison of clinical outcomes between groups and estimated crude and IPTweighted HRs based on all 308 patients. Both crude and weighted HRs of the primary composite end point-the composite of stroke, TIA, or peripheral embolism-were in favor of PFO closure. For the remaining outcomes, crude estimates and estimates derived from IPT-weighted analysis were similar and tended to be in favor of PFO closure, even though CIs were wide and overlapped the line of no difference at 1 in most cases. It was possible to match 103 patients treated with percutaneous PFO closure to 103 medically treated patients. The median follow-up duration among survivors completing the last follow-up was 9 years in both groups (range, 8 -14 years), with an accumulated 966 and 969 patient-years, respectively. Table 1 (right) shows pretreatment characteristics at baseline after matching, which were comparable between groups. Table II in the online-only Data Supplement presents a comparison of antithrombotic regimens at baseline and the last follow-up. In the medical treatment group, 33 of the 103 matched patients (32%) crossed over to subsequent percutaneous (nϭ29) or surgical (nϭ4) PFO closure (Figure 1) . Table 2 presents primary comparisons of clinical outcomes up to 15 years for PS-matched patients. At a median follow-up of 9 years, the primary composite end point occurred in 11 patients treated with percutaneous PFO closure (10.7%) and 22 medically treated patients (21.4%; HR, 0.43; 95% CI, 0.20 to 0.94; Pϭ0.033). Figure 2 shows the Kaplan-Meier curves for the primary composite end point and for stroke, TIA, and all-cause mortality. The lower event rate in favor of percutaneous PFO closure was due mainly to a lower rate of TIAs (4.9% versus 13.6%; HR, 0.31; 95% CI, Figure 3 shows results of stratified analyses for the primary composite end point. Findings varied to some extent across subgroups, but the 95% CIs overlapped, and none of the tests for interaction between treatment effects and stratum were positive despite the multiplicity of testing. Figure 4 presents estimated numbers of events per 100 patients per year and the corresponding unadjusted HRs from an exploratory analysis performed after the follow-up times of the medically treated patients who crossed over to PFO closure were split into episodes during medical treatment and episodes after PFO closure (43 of the 158 medically treated patients) while simultaneously accounting for multiple events occurring in the same patient (multiple events occurred in 1 patient after PFO closure but in 11 patients during medical treatment; Pϭ0.006). Table 3 presents corresponding IPTweighted HRs estimated from all 308 patients (top) and HRs estimated from PS-matched patients (bottom). Estimates became generally more pronounced after accounting for crossovers. Estimated HRs from the exploratory IPTweighted and the PS-matched analyses were compatible, even though the 95% CIs of the latter were considerably wider and overlapped the line of no difference in most cases.
Discussion
In this prospective cohort study with long-term follow-up of up to 15 years, percutaneous PFO closure provided improved clinical outcome compared with medical treatment for the primary end point, a composite of stroke, TIA, or peripheral embolism. The improved clinical outcome was related mainly to TIAs. Stratified analyses did not provide evidence that effect estimates varied according to subgroups. Crossover to PFO closure during follow-up occurred in 43 of 158 patients (27%) who had originally been slated to medical treatment and in 33 of the 103 PS-matched patients (32%). To account for this, follow-up periods were split up into time under medical treatment and time after PFO closure, and multiple events in a given patient were counted. This resulted in a more pronounced benefit of PFO closure and some evidence for improved survival (Figure 4 ). The event rates corre- The major strength of this study is the long follow-up of Ͼ10 years. Included patients were among the first to receive percutaneous PFO closure. Therefore, this study is bound to have the longest follow-up duration available to date, providing robust long-term data on both the effectiveness and safety of percutaneous PFO closure. However, results may be subject to confounding by indication owing to the lack of randomization. A comparison of the 150 patients who received PFO closure with the 158 medically treated patients indicated that the nonrandomized nature of the comparison may have biased results in either direction; medically treated patients tended to be diagnosed with diabetes mellitus more often, whereas patients with PFO closure had more cerebrovascular events and more pronounced right-to-left shunts and were more likely to have hypercholesterolemia. PS matching resulted in full balance of all baseline characteristics and is likely to have minimized confounding by indication. Estimated treatment effects after PS matching and IPT weighting in an analysis of all patients were compatible, which suggests that IPT weighting likewise minimized confounding by indication. These methods are not necessarily more effective in controlling confounding than traditional multivariable regression models. 28 However, the rather low number of events of the primary composite end point and its individual components precluded the inclusion of all relevant variables in traditional multivariable regression, 29 whereas PSs could still be adequately estimated from all relevant variables.
The variation in devices and the use of some devices that are obsolete, even though they were standard of care when PFO closure was introduced at our hospital, represent other limitations; improved devices, techniques, and accompanying drugs have yielded annual recurrence rates Ͻ1%. 22 As for medical treatment, novel oral anticoagulants such as dabigatran 30 are easier to administer and may be associated with improved clinical outcome. However, a bleeding risk persists. 30 Data on other pharmacological cointerventions, including angiotensin-converting enzyme inhibitors and statins, were not prospectively collected. When our study was initiated, these interventions had not been recommended in guidelines for the treatment of stroke patients, and we deem systematic differences between groups unlikely, even though we cannot fully exclude them. In addition, we included patients with definite ischemic strokes and patients with a presumed diagnosis of a TIA as an index event in our study. However, some patients with presumed TIA may not have suffered an ischemic event. These patients would have only a small or no potential benefit from PFO closure, which would result in a dilution of the overall effect of PFO closure. We stratified the analysis according to type of index event and did not find any evidence for this notion. Because both PFO and cryptogenic stroke are prevalent conditions, 6 they may coexist without causal relation in certain patients. Percutaneous PFO closure in patients with strokes that were erroneously attributed to PFO will not influence recurrent events, a circumstance likely to contribute to the small recurrence rate despite successful PFO closure in our series and others. Furthermore, in a previous workup of events that were ascertained during a shorter follow-up in our cohort, only Ϸ60% of recurrent events were classified as cryptogenic, whereas in Ϸ40%, conventional stroke causes such as atrial fibrillation, cerebral artery disease, or thrombophilic disorders were documented. 31 Naturally, PFO closure will affect only paradoxical embolism, whereas events resulting from other causes are bound to be unaffected. In our study, we screened patients at baseline for most of these causes.
Observational studies on medical treatment in patients with PFO with either antiplatelet agents or coumarin reported a risk of recurrent stroke or TIA ranging from 3% to 12% during the first year. [7] [8] [9] [10] [11] [12] According to a recent meta-analysis of 15 studies of medical treatment in 2548 patients with cryptogenic cerebrovascular events, the pooled rate of recurrent ischemic stroke or TIA was 4.0 events per 100 patientyears (95% CI, 3.0 -5.1), whereas the rate of recurrent ischemic stroke was 1.6 events per 100 patient-years (95% CI, 1.1-2.1). 32 A therapeutic intervention to lower this risk further appears justified, particularly because the most effective treatment, coumarin, not only is cumbersome but also carries a substantial long-term risk of bleeding. Medical stroke prevention is often stopped in patients with percutaneous PFO closure as soon as complete occlusion has been ascertained and the substrate for paradoxical embolism has been eliminated.
Percutaneous PFO closure imposes a risk of periprocedural complications. A recent summary of 11 studies with 1970 patients treated with percutaneous PFO closure revealed TIAs in 0.2%, tamponade in 0.3%, device embolization in 1.1%, and puncture-site problems in 1.5% of cases. 25 There were no deaths, myocardial infarctions, strokes, or any other serious adverse events with lasting sequelae. Thrombus formation on the device surface is of concern because it may be associated with thromboembolic complications and may necessitate device removal. It has been reported to be device dependent and is exceedingly rare (Ͻ0.5%) with some devices. 22, 33 Although free-wall device erosion resulting in cardiac tamponade has been described as a rare complication (0.1%), this observation pertains largely to patients with true atrial septal defects and large devices.
Percutaneous PFO closure may be a particularly valuable treatment option in patients with PFO and associated ASA. 7, 10, 19 We did not observe a treatment-by-subgroup interaction with the presence or absence of ASA in our study. Albeit small, this subgroup deserves further examination. Our data at this point of follow-up favor percutaneous PFO closure in all comers over medical treatment. However, the findings of this observational study require confirmation in randomized trials and are applicable only to cryptogenic cerebral events. Ongoing trials may fall short of that goal because the lower-than-expected event rates render the included patient numbers and follow-up duration insufficient to achieve satisfactory power.
The as-yet unpublished CLOSURE I study (A.J. Furlan, oral communication; American Heart Association Annual Scientific Sessions; November 15, 2010; Chicago, IL), the first randomized study reported so far, included patients similar to those in our study (mean age, 46 years; 52% male; 72% cryptogenic stroke; 37% with ASA associated with the PFO). The investigators aimed for a reduction of the composite end point of stroke, TIA, and all-cause mortality for the first 30 days and neurological mortality from 31 days to 2 years from 6% with medical treatment to 2% after PFO closure with the STARFlex device at 2 years. Procedural success was only 90% compared with 99% in our study. Complete closure, as assessed by TEE at 6 months, was achieved in 86% of cases compared with 82% in our study. At 2 years, an intention-to-treat analysis revealed stroke rates of 3.1% in the PFO closure group and 3.4% in medically treated patients, TIA rates of 3.3% and 4.6%, and rates of 5.9% versus 7.7% for the composite end point. Although that trial was negative and our data reached conventional levels of statistical significance for our prespecified primary composite end point, the CIs of the estimated relative risks of our study and CLOSURE I overlap widely, suggesting that the results of the 2 studies are mutually compatible.
Limitations
It has to be assumed that some of the index events (particularly TIAs) might not have been related to the PFO. Restriction of the analysis to patients with unequivocally documented stroke and comprehensive exclusion of any stroke cause other than the PFO might have rendered the differences more conspicuous. Some follow-up events likely are not PFO related, 31 thereby further diluting the actual difference in paradoxical embolisms.
Hypercoagulable states were not systematically looked for, and patients with such states were not systematically excluded. On the one hand, these states may cause embolic or ischemic events not related to the PFO; on the other hand, they enhance the hazard of a PFO.
The nonrandomized nature of the comparison may have resulted into bias. However, at the time the patients were slated to the different treatments, there was virtually no information available to lead to systematic differences between groups. Moreover, PS matching further enhanced the comparability of the patients.
Discrepancies in the performance of the different closure devices used in the patients are likely to have an impact on results. However, the devices were used in a sequential manner, and discarding the earlier devices would have significantly shortened the observation period, a crucial factor in a study looking at the prevention of rare events.
The presentation of the data based on the time of follow-up with an open PFO compared with the time of follow-up with a closed PFO is again subject to bias since closure of the PFO during the observation period was based entirely on physician and patient decisions. However, results are compatible with results from the PS-matched analysis.
The fact that patients were usually taken off platelet aggregation inhibitors a few months after PFO closure may seem suboptimal because some patients may have had index and follow-up events that were independent of the PFO and susceptible to platelet aggregation. However, this behavior could have blunted rather than overestimated the described differences.
A final limitation is that there was no blinded clinical events committee to adjudicate clinical events. However, all events were adjudicated by a senior neurologist according to established criteria.
Conclusion
In this matched study with a follow-up of up to 15 years, percutaneous PFO closure appeared equally effective for secondary stroke prevention and more effective for secondary TIA prevention compared with medical treatment in patients with PFO and a related index event.
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